Fig. 1
Reduced Cyp46A1 protein levels at terminal stages of prion disease in mice. a, b PK-digested (PK +) and undigested (PK-) brain homogenates of mock and prion-infected mice (RML, 22-L and ME-7) were used for immunoblotting and PrP detection using mAb 4H11. No PK-resistant PrPSc (PrPres) was detected in + PK samples in the mock group, while PrPSc was abundantly detected in all prion-infected brain homogenates. c The same brain homogenates of mock and prion-infected mice (RML, 22-L and ME-7) at terminal stage (> 150 days post infection (DPI) were analyzed by immunoblot for Cyp46A1 levels. β-Actin was used as a loading control and was obtained after stripping of the same membrane. The histograms are represented as the means ± SEM (n = 4 mice/group) of three independent experiments. Significance = **p < 0.01; ANOVA followed by Turkey’s post hoc test. d Immunofluorescence images of Cyp46A1 (green) in the cerebellum and medulla regions of mouse brains. Fluorescence intensity was quantified; the histograms represent the means ± SEM of n = 3 mice per group, obtained from 3 independent experiments. Magnification: 10X. Scale bar = 100 μm, 50 μm, 20 μm. Significance = *p < 0.05; Student’s unpaired t test